Clinical trials: Camrelizumab
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC
This retrospective real-world study aimed to compare neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT) followed by esophagectomy in patients with locally advanced esophageal squamous cell carcinoma…
- Trial name
- NCT07236320
- Testing
- Neoadjuvant immunochemotherapy, Neoadjuvant Chemoradiotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Yongtao Han
Uterine Cervical Neoplasms, Oncolytic Virotherapy
H101 Combined With Camrelizumab for Recurrent Cervical Cancer
There is no standard treatment for recurrent cervical cancer that progresses or persists after first-line treatment. The objective response rate of anti-PD-1 antibody treatment is about 15%.
- Conditions
- Uterine Cervical Neoplasms, Oncolytic Virotherapy, Camrelizumab
- Trial name
- NCT05234905
- Testing
- Recombinant human adenovirus type 5＋Camrelizumab
- Where
- 4 sites in China
- Volunteers
- 55 people
- Sponsor
- Zhejiang Cancer Hospital
C-staged Hepatocellular Carcinoma in BCLC Classification
A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification
This study was designed to evaluate the effectiveness and safety of hepatic arterial infusion chemotherapy combined with Apatinib and Camrelizumab (treatment group) versus Apatinib and Camrelizumab (control group) for C-staged…
- Trial name
- TRIPLET-III (NCT05313282)
- Testing
- Hepatic Arterial Infusion combined with Apatinib and Camrelizumab, Apatinib combined with Camrelizumab
- Where
- 5 sites in China
- Volunteers
- 140 people
- Sponsor
- Sun Yat-sen University
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma
- Trial name
- NCT04476459
- Testing
- Camrelizumab, Apatinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Huiqiang Huang
Triple Negative Breast Cancer
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC
The study is being conducted to evaluate the tolerability, safety and efficacy of SHR-1210 in combination with Apatinib and Fluzoparib in subjects with recurrent and metastatic triple negative breast cancer
- Trial name
- NCT03945604
- Testing
- SHR-1210 + Apatinib +Fluzoparib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Esophageal Squamous Cell Carcinoma
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
We plan to conduct a single-center,prospective, Open Label, Randomized Controlled, Phase II Clinical Study of the Combination of Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy in the Treatment of Locally Advanced…
- Trial name
- NCT07312578
- Testing
- Nimotuzumab, camrelizumab, Albumin paclitaxel
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Peking University
Advanced Hepatocellular Carcinoma
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
To evaluate the efficacy and safety of TAE+HAIC combined with camrelizumab and apatinib in the treatment of advanced liver cancer with high tumor load
- Trial name
- NCT06363825
- Testing
- camrelizumab
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Fujian Medical University
Acral Melanoma
Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma
It is a RCT aimed to evaluate the Progression Free Survival of Camrelizumab combined with apatinib and temozolomide as First Line Therapy in Advanced Acral Melanoma.
- Trial name
- NCT05789043
- Testing
- camrelizumab+apatinib+TMZ, camrelizumab+apatinib, camrelizumab
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Peking University Cancer Hospital & Institute
Cervical Cancer
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
This study is a randomized, open-label, controlled, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the…
- Trial name
- NCT04906993
- Testing
- camrelizumab； famitinib malate, platinum-based chemotherapy
- Where
- China
- Volunteers
- 443 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Locally Advanced or Metastatic and Unresectable HCC
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus sorafenib as first-line therapy in patients with advanced HCC.
- Trial name
- NCT03764293
- Testing
- SHR-1210, Apatinib, Sorafenib
- Where
- 121 sites in United States, Belgium and 11 more
- Volunteers
- 543 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Gastric Adenocarcinoma
PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer
This study is a single center, phase II study, to evaluate the effectiveness and safety of PD-1 Antibody(SHR-1210) Plus apatinib Combined With POF(paclitaxel plus oxaliplatin plus 5-fluorouracil plus leucovorin) , in the…
- Trial name
- NCT04174339
- Testing
- Camrelizumab, Apatinib Mesylate, POF
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fujian Cancer Hospital
Esophageal Squamous Cell Carcinoma, Immunotherapy
Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy of Camrelizumab plus concurrent chemotherapy as neoadjuvant approach for patients with opearble esophageal squamous cell carcinoma.
- Trial name
- NCT04225364
- Testing
- camrelizumab, Paclitaxel for injection (albumin-bound), Cisplatin
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Breast Cancer
Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy
This is a phase II, single-arm, multi-center, prospective clinical study of camrelizumab in combination with liposomal doxorubicin and losartan in patients with advanced or locally advanced triple-negative breast cancer who had…
- Trial name
- NCT05097248
- Testing
- Camrelizumab, Liposomal Doxorubicin, Losartan
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gastric Cancer Adenocarcinoma Metastatic
Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
For patients with metastatic gastric cancer, the efficacy of current standard treatments outlined in the guidelines is far from meeting the clinical demand.
- Trial name
- NCT06711471
- Testing
- trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- LIN YANG
BRAF V600E-mutated /MSS Metastatic Colorectal Cancer, Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody
Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
BRAF mutation exists in about 10-12% of colorectal cancer, among which BRAF V600E mutation is the most common type, which is an important biomarker for predicting the prognosis and precise treatment efficacy of metastatic…
- Trial name
- NCT05019534
- Testing
- Vemurafenib Oral Tablet [Zelboraf], Cetuximab Injection [Erbitux], Camrelizumab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- West China Hospital
Melanoma
To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma
This study is being conducted to explore the efficacy and safety of camrelizumab combined with SHR1020 in the treatment of advanced melanoma.
- Trial name
- NCT05051865
- Testing
- camrelizumab, SHR1020
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Nasopharyngeal Carcinoma
Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma
This study is a randomized, placebo-controlled, double-blind, multicenter phase III clinical study. Target population is patients with recurrent/metastatic nasopharyngeal carcinoma who had not received systemic chemotherapy.
- Trial name
- NCT03707509
- Testing
- Camrelizumab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 263 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gastrointestinal Cancer, Immunotherapy
An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal
At present, surgery, radiotherapy and chemotherapy are the main treatment methods for patients with advanced gastrointestinal cancer.
- Conditions
- Gastrointestinal Cancer, Immunotherapy, Targeted Therapy
- Trial name
- NCT05225844
- Testing
- Camrelizumab, Apatinib Mesylate
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Harbin Medical University
Late-stage Resectable Esophageal Squamous Carcinoma
Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
This study is a prospective, exploratory clinical study aimed at evaluating the feasibility and safety of camrelizumab combined with synchronous chemoradiotherapy as an organ-preserving strategy for locally advanced resectable…
- Trial name
- NCT07622797
- Testing
- Camrelizumab (anti-PD-1 inhibitor), Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 164 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Cervical Carcinoma, Chemoradiotherapy
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
This study is a single-center, single-arm, open-phase II clinical study, the main purpose of which is to evaluate the effectiveness and safety of camrelizumab combined with concurrent chemoradiotherapy for early and locally…
- Conditions
- Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1, Immunotherapy
- Trial name
- NCT05311566
- Testing
- Camrelizumab plus Concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Lei Li